Form 4 for KLRA Kailera Therapeutics, Inc.
Accepted 2026-04-20 18:08:42 ET · period of report 2026-04-16 · accession 0001193125-26-164407 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-04-20 18:08 | 2026-04-20 | KLRA | Koppel Adam | Dir, 10% | C - Cnv Deriv | — | +21.02M | 21.02M | New | — |
| DI | 2026-04-20 18:08 | 2026-04-20 | KLRA | Koppel Adam | Dir, 10% | P - Purchase | $16.00 | +1.56M | 22.58M | +7% | +$25.00M |
| DMI | 2026-04-20 18:08 | 2026-04-20 | KLRA | Koppel Adam | Dir, 10% | C - Cnv Deriv | $0.00 | -21.02M | 0 | -100% | $0 |
| D | 2026-04-20 18:08 | 2026-04-16 | KLRA | Koppel Adam | Dir, 10% | A - Grant | $0.00 | +38.3K | 38.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-20 | C | A | 16,875,000 | — | 16,875,000 | I See footnotes | — | — | (F1) Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F4) Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). (F5) Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2026-04-20 | C | A | 4,145,768 | — | 21,020,768 | I See footnotes | — | — | (F2) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F4) Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). (F5) Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 3 | Common | Common Stock | 2026-04-20 | P | A | 1,562,500 | $16.00 | 22,583,268 | I See footnotes | — | — | (F4) Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). (F5) Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 4 | Derivative | Series A-1 Preferred Stock | 2026-04-20 | C | D | 16,875,000 | $0.00 | 0 | I See footnotes | — · — to — | 16,875,000 Common Stock | (F1) Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F1) Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F1) Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F4) Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). (F5) Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 5 | Derivative | Series B Preferred Stock | 2026-04-20 | C | D | 4,145,768 | $0.00 | 0 | I See footnotes | — · — to — | 4,145,768 Common Stock | (F2) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F2) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F2) Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. (F4) Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). (F5) Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 6 | Derivative | Stock Option (right to buy) | 2026-04-16 | A | A | 38,300 | $0.00 | 38,300 | D | $16.00 · — to 2036-04-16 | 38,300 Common Stock | (F3) The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Dr. Koppel's continued service through each such vesting date. |